Alyeska Investment Group, L.P. Arvinas, Inc. Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $5.17 Million - $10.7 Million	-143,525 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$60.27 - $81.57 $433,582 - $586,814	7,194 Added 5.28%	143,525 $9.66 Million
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $5.68 Million - $8.31 Million	86,331 Added 172.66%	136,331 $11.2 Million
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $4.36 Million - $6.43 Million	-59,593 Reduced 54.38%	50,000 $4.11 Million
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $2.53 Million - $4.8 Million	84,593 Added 338.37%	109,593 $3.68 Million
Q3 2018 Nov 14, 2018	BUY	$16.05 - $16.87 $401,250 - $421,750	25,000 New	25,000 $422,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $958M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.